Boston Scientific extends recent slide, shares trail S&P 500 into earnings quarter
25.06.2026 - 19:30:28 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 19:29.
Boston Scientific (US10117L1017) heads toward its next earnings release with shares trading on the NYSE and lagging the S&P 500 over the past month, according to Zacks data.Zacks analysis on BSX performance The stock sits in the S&P 500 medical devices cohort, with consensus pointing to mid-single-digit revenue growth for the upcoming quarter.Nasdaq summary of Boston Scientific estimates
What the latest data shows
In the latest closing session, Boston Scientific shares were down 2.5 percent at 44.46 US dollars, trailing the S&P 500, which lost 0.1 percent on the day, per Zacks.Zacks performance snapshot for BSX Over the previous month, the medical device maker recorded a 20.89 percent decline, while the broader medical sector gained 1.97 percent and the S&P 500 slipped 1.34 percent.Zacks sector comparison
Recent quote data place Boston Scientific around 44.26 US dollars as of late morning New York time, with a market capitalization of roughly 66 billion US dollars, underlining its large-cap status within US healthcare.Realtime listing details for BSX The shares trade under the ticker BSX on the NYSE alongside peers such as Abbott Laboratories and Medtronic in the cardiovascular and broader medical devices space.Arincen overview of Boston Scientific and peers
Analyst estimates and ratings picture
Consensus compiled by Zacks points to second-quarter earnings per share of 0.83 US dollars, up 10.67 percent from the same quarter a year ago, on revenue of 5.39 billion US dollars, a projected 6.54 percent increase.Zacks consensus figures for Q2 2026 For the full year, the Zacks Consensus Estimates stand at 3.36 US dollars earnings per share and 21.61 billion US dollars revenue, implying growth of 9.8 percent and 7.65 percent respectively versus the prior year.Nasdaq coverage of full-year expectations
Zacks currently assigns Boston Scientific a Rank 4 (Sell), reflecting a relatively cautious stance based on their earnings revisions framework.Zacks rating explanation for BSX The valuation metrics cited include a forward price-earnings ratio of around 13.6 and a price-earnings-growth (PEG) ratio near 0.87, suggesting that expected growth is not fully reflected in the current multiple by their methodology.Nasdaq note on BSX valuation metrics
Further news and data on the Boston Scientific shares
More background, key figures and regulatory disclosures on Boston Scientific are available in the dedicated topic overview and on the company's investor relations pages.
The business behind the stock
Boston Scientific generates most of its revenue from minimally invasive medical devices across cardiology, rhythm management, peripheral interventions and endoscopy, among other specialties.Company profile summary for Boston Scientific Flagship products include the Watchman left atrial appendage closure device for stroke risk reduction in atrial fibrillation and a broad portfolio of drug-eluting stents for coronary interventions, alongside implantable cardioverter-defibrillators and neurostimulation systems.Boston Scientific information on Watchman device
Where the stock trades today
The Boston Scientific shares (US10117L1017) trade on the NYSE under the ticker BSX and recently changed hands around 44.26 US dollars as of 2026-06-25, 11:51 New York time, based on consolidated quote data.
Key data on the Boston Scientific shares
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- WKN: 884113
- Ticker: BSX
- Trading venue: NYSE
- Price (as of 2026-06-25, 11:51): 44.26 USD
- Market cap: 66.08 billion USD (as of 2026-06-25)
- Sector / industry: Health Care Equipment & Supplies (medical devices)
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a securities recommendation or an offer to buy or sell financial instruments. All data are based on sources deemed reliable but may be subject to change. Investors should conduct their own research or consult a professional advisor before making investment decisions.
